JACN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Widlansky, M. E.
Right arrow Articles by Vita, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Widlansky, M. E.
Right arrow Articles by Vita, J. A.

Acute EGCG Supplementation Reverses Endothelial Dysfunction in Patients with Coronary Artery Disease

Michael E. Widlansky, MD, Naomi M. Hamburg, MD, Elad Anter, MD, Monika Holbrook, MS, David F. Kahn, MD, James G. Elliott, PhD, John F. Keaney, Jr., MD and Joseph A. Vita, MD

Evans Department of Medicine and Whitaker Cardiovascular Institute, Boston University School of Medicine (M.E.W., N.A.H., E.A., M.H., D.F.K., J.F.K., J.A.V.) Boston, Massachusetts
DSM Nutritional Products, Inc. (J.G.E.) Parsippany, New Jersey


Figure 1
View larger version (15K):
[in this window]
[in a new window]

  		Fig. 1. Outline of Study Design. Subjects were randomly assigned to either the EGCG or Placebo arm first and then crossed over to the other treatment. Bid = twice daily.

 

Figure 2
View larger version (20K):
[in this window]
[in a new window]

  		Fig. 2. Upper Panel: Changes in brachial artery flow-mediated dilation (FMD) compared to pretreatment are displayed for Placebo and EGCG. FMD improved two hours after a single 300 mg dose of EGCG (*P = 0.01), while FMD was not changed after two weeks of EGCG 150 mg twice daily (P = 0.12). Placebo had no effect at the two-hour and two-week time points. Lower Panel: Changes in plasma EGCG concentration compared to pre-treatment concentration are displayed for Placebo and EGCG (n = 38). Plasma ECGC concentrations were increased two hours after a single 300 mg dose of EGCG (P < 0.001), while trough plasma EGCG concentrations (approximately 14 hours after the last dose) were unchanged after two weeks of EGCG 150 mg twice daily. Data are mean ± SEM.

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American College of Nutrition.